上海宣泰医药科技股份有限公司（以下简称"公司"）于 2025 年 12 月 12 日召开第二届董事会第二十一次会议，审议通过了《关于募投项目延期的议案》， 同意公司对首次公开发行股票募集资金投资项目（以下简称"募投项目"）"高 端仿制药和改良型新药研发项目"达到预定可使用状态的时间进行延期，保荐机 构对上述事项出具了明确的核查意见，现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开 发行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金 总额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 4,761.77 万元，实际募集资金净额为人民币 37,721.81 万元。 2022 年 8 月 22 日，上述募集资金已经全部到账并存放于公司募集资金专户 管理。公司对募集资金采取了专户存储制度，设立了相关募集资金专项账户。募 集资金到账后，公司与保荐机构、存放募集资金的银行签署了募集资金专户存储 监管协议 ...

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025), reflecting the recognition of its clinical value by the National Healthcare Security Administration [1][2]. Group 1: Product Information - The product Sitagliptin Metformin Extended-Release Tablets (II) has been included in the National Medical Insurance Catalog (2025) under a national negotiation renewal format [1]. - The inclusion is expected to enhance the affordability and accessibility of the drug for patients, thereby promoting its market expansion and increasing sales volume [1]. Group 2: Impact on the Company - The renewal of the product's inclusion in the National Medical Insurance Catalog is anticipated to have a positive impact on the company's long-term operational development [1]. - The company plans to actively cooperate in implementing the medical insurance policy to benefit more patients [1]. Group 3: Implementation Timeline - The National Medical Insurance Catalog (2025) will officially take effect on January 1, 2026, with specific details on reimbursement standards and policies to be announced by relevant government departments [2].

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operational development despite short-term performance uncertainties [1]. Group 1: Stock Performance - As of December 8, 2025, Xuantai Pharmaceutical (688247) closed at 10.37 yuan, up 0.39% from the previous trading day, with a total market capitalization of 4.701 billion yuan [1]. - The stock opened at 10.36 yuan, reached a high of 10.4 yuan, and a low of 10.3 yuan, with a trading volume of 18.4461 million yuan and a turnover rate of 0.39% [1]. Group 2: Product and Market Impact - The renewed agreement maintains the medical insurance payment standard at 3.47 yuan per tablet, effective from January 1, 2026, to December 31, 2027 [1]. - The product is classified as an oral compound hypoglycemic agent and falls under Category B, which is expected to enhance drug accessibility and market promotion [1].

Core Viewpoint - The company announced that its product, Sitagliptin Metformin Extended-Release Tablets (II), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) through a national negotiation renewal [1] Group 1 - The inclusion of Sitagliptin Metformin Extended-Release Tablets (II) in the national drug list is a significant development for the company [1]

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

证券代码：688247 证券简称：宣泰医药 公告编号：2025-049 升销售规模，对公司的长期经营发展具有积极影响。公司将积极配合推进医保政 策落地，致力于让更多患者受益。 国家医保目录（2025 年）将于 2026 年 1 月 1 日起正式实施，医保支付标准、 医保报销细则等相关信息，需以国家医疗保障局等相关政府部门公示信息为准。 产品的具体销售情况可能会受到市场环境、渠道拓展等多重因素影响，对公司短 期内经营业绩的影响存在不确定性。敬请广大投资者谨慎决策，注意防范投资风 险。 上海宣泰医药科技股份有限公司自愿披露 关于公司产品续约纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据国家医疗保障局网站于 2025 年 12 月 7 日发布的《国家医保局 人力资 源社会保障部关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以 及<商业健康保险创新药品目录>（2025 年）的通知》（医保发〔2025〕33 号）， 上海宣泰医药科技股份有限公司（以下简称"公司"）产品西格列汀二甲双胍缓 释片（ ...

Core Viewpoint - XuanTai Pharmaceutical (688247) announced on December 8 that its product, Sitagliptin Metformin Extended-Release Tablets (II), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) through a national negotiation renewal [1] Company Summary - The product is an oral compound hypoglycemic drug [1]

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025) through a national negotiation process, indicating recognition of the drug's clinical value by the National Healthcare Security Administration [1] Summary by Relevant Categories Product Inclusion - The Sitagliptin Metformin Extended-Release Tablets (II) have been renewed for inclusion in the National Medical Insurance Catalog, reflecting the government's acknowledgment of its clinical value [1] Market Impact - The inclusion in the insurance catalog is expected to enhance the affordability and accessibility of the drug for patients, which will facilitate market promotion and increase sales scale [1] Long-term Development - This development is viewed positively for the company's long-term operational growth, as it aligns with the goal of benefiting more patients through improved healthcare policies [1]

宣泰医药（688247.SH）创始人、董事方云日前做客《沪市汇・硬科硬客》第二季第6期"供应链'再出 海'"时表示，制药行业投入与产出的时间跨度较长，属于典型的长周期行业。 0:00 "我们非常希望与耐心资本合作。公司的回报率不低，只是时间比较长，所以我们需要寻找的是更有耐 心和长远眼光的资本。"方云强调。（中经记者 罗辑 北京报道） ...

0:00 宣泰医药（688247.SH）创始人、董事方云日前做客《沪市汇・硬科硬客》第二季第6期"供应链'再出 海'"时表示，产品在市场上的受重视程度与利润和规模密切相关。 方云表示，若产品利润空间不足，就难以获得足够关注。只有当产品具备充足的利润和较大的市场体 量，才会吸引更高的市场关注度。利润和规摸是产品市场竞争力的核心决定因素。这已经成为全球商业 的共识。（中经记者 罗辑 北京报道） ...